Aclara Biosciences
Aclara Biosciences was a U.S. medical-technology company that developed microfluidic and bioanalytical systems, including its eTag assay platform.
Last updated August 31, 2026
AI crawler reads
No AI crawler has read this profile since Oct 28, 2026.
Overview
Aclara Biosciences was a United States medical-technology and biotechnology company focused on applying microfluidics to laboratory testing. The business began in Delaware in 1995 under the name Soane BioSciences, Inc. and adopted the Aclara Biosciences name in 1998. It later moved its headquarters to Mountain View, California, placing it within the San Francisco Bay Area biotechnology and laboratory-technology ecosystem. The company developed miniaturized analytical technologies intended to support the handling, separation, detection, and analysis of biological materials. Its best-known platform was eTag, short for electrophoretic tag, an assay technology designed for work involving proteins and nucleic acids. Rather than operating primarily as a conventional pharmaceutical developer, Aclara occupied the medical-device and laboratory-tools segment of biotechnology, seeking to make complex bioanalytical procedures more integrated and information-rich. Aclara became a public company in March 2000, when it completed an initial public offering of 9 million shares on NASDAQ under the symbol ACLA. Its public-market period was marked by significant intellectual-property litigation with Caliper Technologies, another company active in microfluidics. Caliper alleged that Aclara had misappropriated trade secrets relating to microfluidic technology. The dispute formed part of a broader series of legal conflicts in which the two companies also accused one another of patent infringement. In October 2000, a California jury found against Aclara in the trade-secret case and awarded Caliper $52.568 million. The company continued developing and testing its assay technologies. In October 2004, Aclara entered into an arrangement with GlaxoSmithKline to evaluate its assays for possible applications in cancer-drug development. This collaboration illustrated the intended role of Aclara's technology: providing analytical capabilities that could assist pharmaceutical research rather than serving as a therapeutic product in its own right. Aclara's independent corporate existence ended through a stock acquisition by Virologic. A proposed transaction announced in 2004 valued the deal at approximately $180 million in Virologic stock, while the completed transaction in December 2004 was reported at approximately $160 million in stock. Under the completed exchange, Aclara shareholders received 1.7 Virologic shares for each Aclara share. Following the acquisition, Aclara no longer operated as an independent publicly traded company. The company was reported to have received 96 patents during its history, reflecting its emphasis on proprietary microfluidic and bioanalytical methods.
History
Aclara Biosciences originated in 1995 as Soane BioSciences, Inc., a Delaware company working in the emerging field of microfluidics and biological analysis. Microfluidics seeks to perform laboratory operations using very small volumes of fluid within miniaturized channels and devices. For companies in this field, the technology had potential applications in clinical and research testing, pharmaceutical discovery, and the analysis of proteins and nucleic acids. In 1998, Soane BioSciences changed its name to Aclara Biosciences, Inc. The renaming reflected the company's move toward a distinct commercial identity in medical technology and laboratory analysis. Aclara subsequently relocated its headquarters to Mountain View, California. The move placed the company near the biotechnology, semiconductor, and analytical-instrument communities of Silicon Valley, although the available reference material does not establish the precise business rationale for the relocation. Aclara entered the public markets in March 2000 through an initial public offering of 9 million shares on NASDAQ. Its trading symbol was ACLA. The flotation gave the company access to public equity markets during a period when microfluidics and laboratory automation attracted substantial interest from investors and technology companies. The same period brought a major legal challenge. In 2000, Caliper Technologies sued Aclara, alleging that Aclara had misappropriated Caliper trade secrets connected with microfluidic technology. The dispute was part of a wider pattern of litigation between the companies, which also accused each other of patent infringement. On October 26, 2000, a California jury found Aclara liable for trade-secret misappropriation and awarded Caliper $52.568 million. This judgment became one of the defining events in Aclara's public corporate history and underscored the importance of proprietary know-how and patent rights in the microfluidics sector. Aclara's principal technology was eTag, or electrophoretic tag, an assay platform intended for use with proteins and nucleic acids. The company received 96 patents during its history, according to the reference material. The platform represented Aclara's effort to commercialize microfluidics not merely as an underlying engineering technique but as a usable bioanalytical system for laboratory and pharmaceutical applications. In October 2004, Aclara entered into an arrangement with GlaxoSmithKline to test its assays for possible use in cancer-drug development. The arrangement linked Aclara's analytical technology to a major pharmaceutical research program, but the available material does not establish the eventual technical or commercial outcome of the testing. Aclara's independent existence concluded in 2004. Virologic proposed to acquire the company in a stock transaction reported at approximately $180 million, equivalent at the time to $4.78 per Aclara share. Virologic completed the acquisition in December 2004 for approximately $160 million in stock, with Aclara shareholders receiving 1.7 Virologic shares for each Aclara share. The acquisition removed Aclara from the public market as a standalone company and ended its operation as an independent corporate brand. The sources supplied do not document the subsequent treatment of individual Aclara products, patents, or employees.
- 2004
GlaxoSmithKline assay-testing arrangement
[1]Aclara agreed to test its assays for potential cancer-drug-development applications with GlaxoSmithKline.
- 2004
Acquired by Virologic
[1]Virologic completed its acquisition of Aclara in December, ending Aclara's status as an independent public company.
- 2000
NASDAQ initial public offering
[1]Aclara completed an initial public offering of 9 million shares and traded on NASDAQ under ACLA.
- 2000
Caliper trade-secret judgment
[1]A California jury found Aclara liable for misappropriating Caliper trade secrets and awarded $52.568 million in damages.
- 1998
Company renamed Aclara Biosciences
[1]The company adopted the Aclara Biosciences, Inc. name.
- 1995
Company founded as Soane BioSciences
[1]Soane BioSciences, Inc. was established in Delaware as the predecessor to Aclara Biosciences.
Products and positioning
Microfluidic bioanalysis and laboratory-testing technology for research and pharmaceutical-development applications
Bioanalytical assay platform
eTag assay technology
eTag, an abbreviation for electrophoretic tag, was Aclara's best-known proprietary assay technology. It was designed for analytical work involving proteins and nucleic acids and formed the technological core of the company's microfluidic bioanalysis proposition. The platform was intended for laboratory and pharmaceutical-research use, including evaluation for cancer-drug development in an arrangement with GlaxoSmithKline. The available material does not identify individual commercial product models, regulatory clearances, or the platform's post-acquisition status.
Laboratory testing technology
Microfluidic bioanalytical systems
Aclara developed applications of microfluidics for laboratory testing. These systems sought to miniaturize and integrate analytical operations involving biological samples, with potential value in research laboratories, biomedical analysis, and pharmaceutical development. Public references describe the technology area and the company's patent activity but do not provide enough information to identify a complete catalog of instruments, consumables, or software products.
Controversies
2000
Caliper Technologies trade-secret litigation
Caliper Technologies alleged that Aclara misappropriated trade secrets relating to microfluidic technology. On October 26, 2000, a California jury found Aclara liable and awarded Caliper $52.568 million. The dispute occurred amid broader patent and intellectual-property litigation between the two companies.
Brand decisions
2004
Accept acquisition by VirologicM&ABackground
Aclara was operating as a public microfluidics and bioanalysis company when Virologic proposed a stock acquisition.
Action taken
Virologic completed the acquisition in December 2004. Aclara shareholders received 1.7 Virologic shares for each Aclara share.
Aftermath
Aclara ceased to exist as an independent publicly traded company. The completed transaction was reported at approximately $160 million in stock.
Reported transaction value. $160 million in Virologic stock (December 2004 completed acquisition)
2004
Evaluate eTag assays for cancer-drug developmentStrategyBackground
Aclara sought to extend the use of its protein and nucleic-acid assay technology into pharmaceutical research.
Action taken
The company entered an arrangement with GlaxoSmithKline to test its assays for potential cancer-drug-development applications.
Aftermath
The available sources do not document the ultimate results or commercialization outcome of the testing arrangement.
Recent events
- 2004
Aclara enters assay-testing arrangement with GlaxoSmithKline[1]
Other
Aclara agreed with GlaxoSmithKline to test its eTag assays for potential use in cancer-drug development.
- 2004
Virologic completes acquisition of Aclara Biosciences[1]
M&A
Virologic completed its stock acquisition of Aclara in December 2004. Aclara shareholders received 1.7 Virologic shares for each Aclara share.
- 2000
Aclara Biosciences completes NASDAQ initial public offering[1]
Other
Aclara completed an initial public offering of 9 million shares on NASDAQ under the symbol ACLA.
Sources1 sources
Cite this profile: Cite the canonical profile. /brand-wiki/aclara-biosciences · Editorial policy · How profiles are compiled